Market need Antibacterial Ostaguard surface technology addresses infection risk in implantable devices across spinal, orthopedic, breast reconstruction, cardiac, neuromodulation, and hearing implants, presenting multiple cross-specialty sales opportunities with high clinical impact.

Commercialization momentum Active leadership changes and board additions in 2024 signal a push toward faster market adoption; leverage executive and strategic advisor networks to accelerate partnerships with device manufacturers and hospitals.

Partnership model Collaborative approach with medical device manufacturers, hospitals, and surgeons offers channel-based sales routes; target co-development and integration deals that align Ostaguard with existing platforms and workflows.

Target customers Small to midsize device-focused manufacturers and high-infection-risk segments present near-term upside, complemented by larger OEMs seeking infection-prevention differentiation without workflow disruption.

Proof of value Current revenue between one and ten million with proven biocompatibility and device performance advantages positions Orthobond for ROI-focused discussions; emphasize reduced revisions and postoperative complications to justify adoption.